These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 6454383)

  • 21. Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function.
    Ohkawa M; Hirano S; Tokunaga S; Motoi I; Shoda R; Ikeda A; Sugata T; Sawaki M; Shimamura M; Okasho A; Kuroda K
    Antimicrob Agents Chemother; 1983 Jan; 23(1):31-5. PubMed ID: 6572490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cefazolin and moxalactam pharmacokinetics after simultaneous intravenous infusion.
    Polk RE; Kline BJ; Markowitz SM
    Antimicrob Agents Chemother; 1981 Nov; 20(5):576-9. PubMed ID: 6459759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative pharmacokinetics of moxalactam, cefoperazone, and cefotaxime in normal volunteers.
    Standiford HC; Drusano GL; McNamee WB; Tatem B; Ryan PA; Schimpff SC
    Rev Infect Dis; 1982; 4 Suppl():S585-94. PubMed ID: 6296967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Moxalactam epimer kinetics in children.
    Nahata MC; Durrell DE; Barson WJ
    Clin Pharmacol Ther; 1982 Apr; 31(4):528-32. PubMed ID: 6460588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Steady-state moxalactam kinetics: comparisons with other cephalosporins.
    Garzone P; Lyon J; Yu VL; Zuravleff J; Diven W; Pasculle W
    Clin Pharmacol Ther; 1981 Jul; 30(1):86-94. PubMed ID: 6453677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of ceftazidime in patients with renal insufficiency.
    Welage LS; Schultz RW; Schentag JJ
    Antimicrob Agents Chemother; 1984 Feb; 25(2):201-4. PubMed ID: 6370127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Moxalactam pharmacokinetics in children.
    Romagnoli MF; Flynn K; Siber GR; Goldmann DA
    Antimicrob Agents Chemother; 1982 Jul; 22(1):47-50. PubMed ID: 6214997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of cefmetazole in normal subjects and in patients with impaired renal function.
    Ohkawa M; Orito M; Sugata T; Shimamura M; Sawaki M; Nakashita E; Kuroda K; Sasahara K
    Antimicrob Agents Chemother; 1980 Sep; 18(3):386-9. PubMed ID: 6932824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels.
    Wise R; Baker S; Livingston R
    Antimicrob Agents Chemother; 1980 Sep; 18(3):369-71. PubMed ID: 6252833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pharmacology of moxalactam in patients with malignant disease.
    Estey EH; Weaver SS; Ho DH; Bodey GP
    Antimicrob Agents Chemother; 1981 Apr; 19(4):639-44. PubMed ID: 6454389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of moxalactam in elderly subjects.
    Andritz MH; Smith RP; Baltch AL; Griffin PE; Conroy JV; Sutphen N; Hammer MC
    Antimicrob Agents Chemother; 1984 Jan; 25(1):33-6. PubMed ID: 6703682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical evaluation of a new broad-spectrum oxa-beta-lactam antibiotic, moxalactam, in neonates and infants.
    Schaad UB; McCracken GH; Threlkeld N; Thomas ML
    J Pediatr; 1981 Jan; 98(1):129-36. PubMed ID: 6450277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of moxalactam in neonates and young infants.
    McCracken GH; Schaad UB
    Rev Infect Dis; 1982; 4 Suppl():S595-6. PubMed ID: 6218569
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacokinetics of intravenous and intraperitoneal moxalactam in chronic ambulatory peritoneal dialysis.
    Albin H; Ragnaud JM; Demotes-Mainard F; Vincon G; Wone C
    Eur J Clin Pharmacol; 1986; 30(3):299-302. PubMed ID: 3732364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity, stability, and pharmacology of the epimers of moxalactam.
    Wise R; Wright N; Wills PJ
    Rev Infect Dis; 1982; 4 Suppl():S564-8. PubMed ID: 6218567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.
    Kemmerich B; Lode H; Belmega G; Jendroschek T; Borner K; Koeppe P
    Antimicrob Agents Chemother; 1983 Mar; 23(3):429-34. PubMed ID: 6303213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.
    Lüthy R; Blaser J; Bonetti A; Simmen H; Wise R; Siegenthaler W
    Rev Infect Dis; 1982; 4 Suppl():S581-4. PubMed ID: 6296966
    [No Abstract]   [Full Text] [Related]  

  • 38. Steady-state moxalactam pharmacokinetics in patients: noncompartmental versus two-compartmental analysis.
    Swanson DJ; Reitberg DP; Smith IL; Wels PB; Schentag JJ
    J Pharmacokinet Biopharm; 1983 Aug; 11(4):337-53. PubMed ID: 6668547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of cefamandole in patients with renal impairment.
    Czerwinski AW; Pederson JA
    Antimicrob Agents Chemother; 1979 Feb; 15(2):161-4. PubMed ID: 426510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Penetration of ocular tissues and fluids by moxalactam in rabbits with staphylococcal endophthalmitis.
    Kane A; Barza M; Baum J
    Antimicrob Agents Chemother; 1981 Nov; 20(5):595-9. PubMed ID: 6459761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.